Dudediligence.

Zymeworks Inc

ZYMENASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$16.0MSep ’24$31.0MDec ’24$27.1MMar ’25$48.7MJun ’25$27.6MSep ’25$2.5MDec ’25$2.4MMar ’26$4.6MJun ’26
Net income, by quarter
−$29.9MSep ’24−$23.5MDec ’24−$22.6MMar ’25$2.3MJun ’25−$19.6MSep ’25−$41.2MDec ’25−$44.2MMar ’26−$45.0MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$26.7M$412.5M$76.0M$76.3M$106.0M
Operating income−$215.6M$130.5M−$138.1M−$137.1M−$92.5M
Net income−$211.8M$124.3M−$118.7M−$122.7M−$81.1M
Operating cash flow−$192.5M$144.1M−$118.3M−$110.1M−$33.0M
Free cash flow−$204.9M$136.0M−$120.8M−$112.0M−$34.5M
Cash$201.9M$400.9M$157.6M$66.1M$41.2M
Shares outstanding46.6M63.1M70.1M69.0M74.6M